Pricing & Access· May 22, 2026 · 12 min read
ASP lag after launch: why buy-and-bill economics can break in the first quarters
By Ran Chen#Medicare Part B#ASP#Buy and Bill
Topic
Reimbursement
Provider reimbursement, claims processing, ASP/WAC pricing, buy-and-bill economics, and revenue-cycle management for specialty drugs.
Pricing & Access· May 22, 2026 · 9 min read
J-code timing and interim billing risk for new buy-and-bill biologics
By Ran Chen#Medicare Part B#HCPCS#J-Code
Specialty· May 22, 2026 · 11 min read
Site-of-care edits for IV and subcutaneous specialty drugs
Specialty· May 22, 2026 · 11 min read
White bagging and brown bagging policies for infusion biologics
By Ran Chen#Specialty Pharmacy#Buy and Bill#Oncology